Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Blue Trust Inc.

by · The Cerbat Gem

Blue Trust Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 22.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,249 shares of the medical research company’s stock after acquiring an additional 225 shares during the quarter. Blue Trust Inc.’s holdings in Thermo Fisher Scientific were worth $621,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $25,000. FPC Investment Advisory Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. Pillar Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $29,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at about $30,000. Finally, Noble Wealth Management PBC purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at about $35,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Up 1.2%

NYSE TMO opened at $397.31 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The stock has a 50 day simple moving average of $412.62 and a two-hundred day simple moving average of $487.84. The stock has a market cap of $149.98 billion, a P/E ratio of 23.30, a price-to-earnings-growth ratio of 2.07 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter last year, the business posted $5.11 EPS. The business’s revenue was up .2% on a year-over-year basis. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. Scotiabank decreased their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research note on Friday, April 25th. Royal Bank Of Canada lowered their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $605.30.

View Our Latest Report on Thermo Fisher Scientific

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).